Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2012 Oct 30;71(2):331–344. doi: 10.1007/s00280-012-2010-z

Table 2.

Metabolites of kb-NB142-70 and its methoxy analogue kb-NB165-09 characterized by LC-MS/MS in urine (U) and plasma (P).

Peak NB165-09 NB142-70 LC-MS/MS
(min)		 [M+H]+
(m/z)		 Product ions Postulated
designation
MS1 U U 5.5 268 251, 226, 223, 222, 208,
193, 189, 182, 177, 162,
153, 150, 148, 137, 121		 kb-NB142-70
-sulfoxide-(O)
OR
-aromatic OH
MS2 U U, P 5.8 428 252, 248, 234, 209, 207,
189, 181, 163, 137		 kb-NB142-70
-Gluc
MS3 - U 6.3 268 217, 207, 189, 181, 177,
163, 150, 145, 137, 121		 kb-NB142-70
-alkyl-OH
MS4 U - 7.6 298 280, 263, 238. 235, 234,
220, 209, 207, 203, 192,
177, 166, 165, 160, 151,
150, 121		 kb-NB165-09
-alkyl-OH
-[O]
MS5 U - 7.8 445 322, 296, 282, 277, 251,
239, 237, 225, 211, 205,
195, 177, 168		 ?
MS6 U, P - 8.2 282 265, 240, 222, 203, 196,
191, 177, 164, 153, 134,
121		 kb-NB165-09
-sulfoxide-(O)
OR
-aromatic-OH
MS7 - U 8.7 428 252, 248, 234, 209, 207,
189, 181, 163, 137		 kb-NB142-70
-Gluc
MS8 U, P - 9.0 282 264, 231, 221, 206, 191,
190, 188, 178, 177, 164,
160, 134, 121		 kb-NB165-09
-alkyl-OH
MS9 U - 9.4 545 298, 248, 231, 204, 171,
153, 143, 135, 107		 ?
MS10 U U, P 9.5 252 503 (di-mer), 234, 209,
207, 189, 181, 163, 153,
145, 137, 109		 kb-NB142-70
MS11 U - 9.6 298 280, 256, 253, 238, 221,
204, 196, 189, 161, 148,
140, 115		 kb-NB165-09
-alkyl-OH
-[O]
MS12 U - 12.9 298 253, 237, 235, 223, 209,
207, 195, 192, 177, 165,
164, 163, 150, 135, 121,
108		 kb-NB165-09
-sulfoxy-(O)2
MS13 U U 13.5-14.5
11.2-13.5		 583/503/332 252, 234, 209, 207, 189,
181, 179, 163, 153, 137		 kb-NB142-70
multimer?
MS14 U, P - 14.8 266 248, 223, 221, 206, 195,
190, 178, 177, 165, 152,
151, 134, 121, 108		 kb-NB165-09
MS15 U - 15.8 312 237, 222, 209, 204, 194,
193, 179, 177, 176, 165,
163, 150, 147, 135, 134,
121		 kb-NB165-09
-alkyl =O
-sulfoxy-(O)2

Gluc, glucuronide.